Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
Laura Levy, DHSc, PA-C
OBJECTIVES: The objective of this selective EBM review is to determine whether or not radioembolization is safer treatment comparing to chemoembolization in patients with primary liver cancer (HCC)
STUDY DESIGN: Review of three English language primary randomized controlled studies published between 2014 and 2016.
DATA SOURCES: Three randomized controlled trials (RCT) were found using PubMed and Medline database.
OUTCOMES MEASURED: Eligible patients were randomly selected and divided into two groups: one group received radioembolization with Y-90 (TARE Y-90) while the other group received chemoembolization (TACE). Adverse events after post treatment were recorded and compared between TARE Y-90 and TACE.
RESULTS: The study by El Fouly et al. (2014) found that less adverse events occurred in patients receiving TARE Y-90 comparing to patients receiving TACE. The study by Kolligs et al. (2015) found that gastrointestinal (GI) adverse events were more common in TARE Y-90 treatment group than TACE treatment group. Overall, the results from Kolligs et al. study showed no significant difference of adverse events between TARE Y-90 and TACE group. The study by Salem et al. (2016) also found that the frequency of adverse events in both TARE Y-90 and TACE group was similar.
CONCLUSIONS: Results from two randomized controlled trials demonstrate that both TARE Y-90 and TACE could cause similar adverse events in HCC patients. The third randomized controlled trial indicate that TARE Y-90 is superior than TACE regarding safety.
Vu, Tram, "Is Radioembolization a Safer Treatment than Chemoembolization in Patients with Primary Liver Cancer (HCC)?" (2019). PCOM Physician Assistant Studies Student Scholarship. 436.